Agilent Technologies (A) climbed about 14.7% over the trailing 30 days, rising from roughly $138.57 to a close near $159.00. The advance pushed the stock to a new 52-week high of $160.51, extending a broader rally that began after its fiscal Q2 2026 earnings beat in late May.

SNAP fell -9.46% during regular-session trading, dropping to about $5.36 from a prior close of $5.92. Primary catalyst: Pennsylvania's attorney general sued Snapchat, alleging addictive features like Snapstreaks and disappearing messages harm minors.

EMAT is trading down -12.44% during regular market hours, at about $3.45 versus the prior close of $3.94. The primary catalyst is a disclosure that the company carries $25.8 million in convertible debt, with $20 million still undrawn, and needs additional financing to fund its growth plans.

SYRE fell -13.8% to $92.54, extending an after-hours drop that began Tuesday after the Phase 2 SKYWAY rheumatoid arthritis (RA) readout. The primary catalyst: SPY072 (a TL1A inhibitor) beat placebo but missed the company's internal efficacy bar, so Spyre will not advance it as an RA monotherapy.

Horizon Quantum (HQ) is down -13.47% to roughly $16.77 during the regular session, after closing the prior session at $19.38. No company-specific news, filing, or earnings catalyst surfaced; the drop appears driven by profit-taking and rotation within the volatile quantum-computing group.

BVC shares fell -16.23% during regular trading, sliding from 14.73 to 12.34 (in thousands of COP). The move is a mechanical ex-dividend adjustment: the stock began trading without entitlement to its large annual dividend.

QFIN fell -18.47% to $9.40 during Wednesday's regular session, versus a prior close of $11.53, touching a fresh 52-week low. The move followed Q2 2026 results released after Tuesday's close: net revenue missed consensus by roughly -11% and non-GAAP net profit nearly halved quarter-over-quarter.

VCIG is down -7.75% to $2.62 in regular-session trading, sliding from a prior close of $2.84. The decline extended a multi-day selloff, with shares down from roughly $3.69 a week ago.

Cre8 Enterprise (CRE) soared +142.47% during regular market hours, climbing from a prior close of $2.59 to about $6.28. The rally followed a company announcement that its customer base and project backlog both hit record levels as of June 30, 2026.

SOAR is up roughly +69.63% intraday, trading near $0.265 versus Tuesday's $0.1564 close, with the surge starting in premarket and holding through the regular session. Primary catalyst: Volato signed a definitive agreement to merge with Alignment Engine, an AI infrastructure company, in a transaction valuing Alignment Engine at about $500 million.

YYGH is trading up +64.35% to about $1.89, extending a rally that ignited in after-hours trading following Tuesday's regular-session close. Primary catalyst: the company announced a supplemental agreement canceling its $5.94M second convertible note tranche and all 11,284 outstanding warrants.

Amazon shares surged roughly 11.9% over the past 30 days, driven overwhelmingly by a blockbuster Q2 2026 earnings report that far exceeded Wall Street expectations. AWS delivered its fastest revenue growth in 18 quarters at 37%, with AI and custom chip businesses each surpassing $25 billion in annualized revenue run rates.

Cre8 Enterprise (CRE) shares surged roughly 135% over the 30 days through late August 2026, a move driven almost entirely by a single-day rally on August 26. The catalyst was a business update revealing a record 550 customers as of June 30, 2026, up 17.8% from year-end 2025 and 34.8% year over year.

DY is down -13.24% to $305.22 during the regular session, extending a multi-day slide from its prior close of $351.80. The drop came despite a fiscal Q2 beat: adjusted EPS of $5.29 and revenue of $2.01B topped consensus of roughly $4.70 and $1.98B.

SMTC is up +10.06% during regular trading, rising from $127.52 to $140.35. Primary catalyst: Q2 FY2027 earnings beat — record revenue of $341.9M (+33% YoY) and adjusted EPS of $0.71 vs $0.61 expected.

ANF surged +27.89% to $139.27 during regular trading, up from $108.90 prior close. Q2 FY2026 earnings beat: EPS of $4.17 vs $1.98 consensus, revenue of $1.27B vs $1.25B expected.

JKS fell -8.90% to $14.12 during regular trading, down from a prior close of $15.50. The decline followed Q2 2026 results released before the open, with revenue down -31.3% year-over-year to RMB12.36 billion.

GENB fell -16.78% to roughly $16.96 during regular market hours, reversing the prior session's +15% surge to $20.38. The primary catalyst is the expiration of the post-IPO lock-up, freeing roughly 103 million restricted shares (about 80% of shares outstanding) for potential sale by insiders and early investors.

QFIN fell -9.80% to $10.40 during the regular session, extending an after-hours slide that began following Tuesday's Q2 earnings release. Primary catalyst: disappointing Q2 results, with net income down sharply to RMB401.4M from RMB1.73B a year earlier and revenue down -31.5% year-over-year.

SYRE fell -14.74% to $91.54, down from the prior session's close of $107.36, with the decline beginning in premarket trading and extending into the regular session. The primary catalyst was topline data from the Phase 2 SKYWAY-RA sub-study of SPY072, which met statistical significance on key endpoints but did not meet the company's internal bar to prioritize SPY072 as an RA monotherapy.